Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
J Cell Biochem. 2017 Dec;118(12):4163-4169. doi: 10.1002/jcb.26118. Epub 2017 Jun 22.
Cervical cancer is a common gynecological cancer and a leading cause of cancer-related death in women globally. There is a need for the identification of prognostic and predictive biomarker for risk stratification. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is often dysregulated in cervical cancer, indicating that it may be a potential therapeutic target in the treatment of this malignancy, and could perhaps be used as a novel biomarker in the assessment of risk of developing cervical cancer. We aimed to provide an overview of the potential applications of the PI3K/Akt/mTOR pathway as biomarker for risk stratification, in predicting the prognosis of cervical cancer, and for developing new therapeutic approaches in patients with cervical cancer. J. Cell. Biochem. 118: 4163-4169, 2017. © 2017 Wiley Periodicals, Inc.
宫颈癌是一种常见的妇科癌症，也是全球女性癌症相关死亡的主要原因。因此，我们需要寻找用于风险分层的预后和预测生物标志物。在宫颈癌中，磷酸肌醇 3-激酶/蛋白激酶 B/雷帕霉素靶蛋白（PI3K/Akt/mTOR）途径经常失调，这表明它可能是治疗这种恶性肿瘤的潜在治疗靶点，并且可以作为评估宫颈癌发病风险的新型生物标志物。我们旨在提供 PI3K/Akt/mTOR 途径作为风险分层生物标志物、预测宫颈癌预后以及为宫颈癌患者开发新的治疗方法的潜在应用的概述。细胞生化学杂志 118:4163-4169, 2017。© 2017 年 Wiley 期刊出版公司
